Loading organizations...
Loading organizations...
Develops single-domain antibody therapies for viral infections.
ExeVir Bio has raised $105.5M across 4 funding rounds.
ExeVir Bio has raised $105.5M in total across 4 funding rounds.
ExeVir Bio has raised $105.5M in total across 4 funding rounds.
ExeVir Bio's investors include VLAIO, Kris Peeters, Philippe Monteyne, Belgian family offices, Noshaq, Sambrinvest, Stef HEYLEN, MD, Caroline THIELEN, Erica Whittaker, Katja Rosenkranz, Jerome Van Biervliet, Joël Henneghien.
ExeVir Bio has raised $105.5M across 4 funding rounds. Most recently, it raised $1.8M Grant in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 28, 2023 | $1.8M Grant | VLAIO | |
| Jan 9, 2023 | $26.7M Debt | Kris Peeters | |
| May 24, 2021 | $50.0M Series A | Philippe Monteyne | Belgian family offices, Noshaq, Sambrinvest, Stef HEYLEN, MD, Caroline THIELEN, Erica Whittaker, Katja Rosenkranz, Jerome Van Biervliet, Joël Henneghien |
| Jul 28, 2020 | $27.0M Other Equity | Philippe Monteyne | SFPI-FPIM, Erica Whittaker, Katja Rosenkranz, Jerome Van Biervliet |